Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7Thoracic 1Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 3Neoplasm Metastasis 2Mesothelioma, Malignant 2Melanoma 2Lung Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Small Cell Lung Carcinoma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Glioma 1Glioblastoma 1

Interventions

pembrolizumab 3Paclitaxel 3Nivolumab 2Drug Therapy 2Bevacizumab 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1spartalizumab 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1regorafenib 1pazopanib 1motexafin gadolinium 1fludarabine 1erythromycin propionate-N-acetylcysteinate 1epacadostat 1depatuxizumab mafodotin 1cobimetinib 1cediranib 1cc-486 1carboxyamido-triazole 1capmatinib 1bemcentinib 1aflibercept 1abiraterone 1abemaciclib 1Uncertainty 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × abemaciclib × Thoracic × Clear all
NCT06810544 2026-04-13

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Tango Therapeutics, Inc.

Phase 1/2 Recruiting
191 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Glioma, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡